60703-69-7

Basic information

• Product Name: 1-(2-BENZHYDRYLOXY-ETHYL)-PIPERAZINE
• Synonyms: BUTTPARK 91\06-12;1-(2-BENZHYDRYLOXY-ETHYL)-PIPERAZINE;AKOS BBS-00003635;1-[2-(diphenylmethoxy)ethyl]piperazine
• CAS NO: 60703-69-7
• Molecular Formula: C₁₉H₂₄N₂O
• Molecular Weight: 296.41
• Mol File: 60703-69-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-BENZHYDRYLOXY-ETHYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BENZHYDRYLOXY-ETHYL)-PIPERAZINE(60703-69-7)
• EPA Substance Registry System: 1-(2-BENZHYDRYLOXY-ETHYL)-PIPERAZINE(60703-69-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 60703-69-7(Hazardous Substances Data)

Usage

Description

1-(2-Benzhydryloxy-ethyl)-piperazine, with the molecular formula C19H24N2O and a molecular weight of 300.408 g/mol, is a chemical compound belonging to the class of piperazine derivatives. It features an ethyl group and a benzhydryl ether group, which may contribute to its potential applications in the fields of pharmacology and medicinal chemistry. The presence of the piperazine moiety, a common structural component in many pharmaceutical drugs, suggests that 1-(2-Benzhydryloxy-ethyl)-piperazine could have significant uses. However, further research and testing are necessary to fully comprehend its potential applications and properties.

Uses

Used in Pharmaceutical Industry:
1-(2-Benzhydryloxy-ethyl)-piperazine is used as a chemical intermediate for the synthesis of various pharmaceutical drugs due to its piperazine moiety, which is a common structural component in many medications. Its unique structure, including the ethyl group and benzhydryl ether group, may provide additional benefits in drug development.
Used in Medicinal Chemistry Research:
1-(2-Benzhydryloxy-ethyl)-piperazine serves as a valuable compound in medicinal chemistry research, where it can be used to explore new drug candidates and optimize existing ones. Its structural features may offer novel avenues for the development of therapeutic agents with improved efficacy and reduced side effects.

Upstream product

• 110-85-0 piperazine 
• 32669-06-0 1,1'-[(2-chloroethoxy)methylene]bis-benzene 
• 142-63-2 piperazine hexahydrate 
• 91-01-0 1,1-Diphenylmethanol 
• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 76-26-6 camphor-10-sulfonic acid 
• 1065099-83-3 tert-butyl 4-(2-(benzhydryloxy)ethyl)piperazine-1-carboxylate 
• 1345012-35-2 tert-butyl 4-(2-iodoethyl)piperazine-1-carboxylate 
• 77279-24-4 tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 

Downstream Products

• 103157-52-4 1-(2-benzhydryloxy-ethyl)-4-(2-phenoxy-ethyl)-piperazine 
• 924605-12-9 [4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-benzo[b]thiophen-2-yl-methanone 
• 1026914-63-5 [4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-naphthalen-2-yl-methanone 
• 1025984-06-8 (E)-1-[4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-3-furan-2-yl-propenone 
• 96177-31-0 1-(2-benzhydryloxy-ethyl)-4-[2-(2-ethyl-butoxy)-ethyl]-piperazine 
• 254984-92-4 3-[4-(2-benzhydryloxy-ethyl)-piperazin-1-yl]-1-phenyl-propan-1-one 
• 1026269-06-6 (E)-1-[4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-3-(4-methoxy-phenyl)-propenone 
• 1027186-14-6 (E)-1-[4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-3-(2-methoxy-phenyl)-propenone 
• 1027163-04-7 (E)-1-[4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-3-(3-methoxy-phenyl)-propenone 

Relevant articles and documents

Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH 1R, but low affinity to hH4R

In literature, a synergism between histamine H1 and H 4 receptor is discussed. Furthermore, it was shown, that the combined application of mepyramine, a H1 antagonist and JNJ7777120, a H 4 receptor ligand leads to a synergistic effect in the acute murine asthma model. Thus, the aim of this study was to develop new hybrid ligands, containing one H1 and one H4 pharmacophor, connected by an appropriate spacer, in order to address both, H1R and H 4R. Within this study, we synthesized nine hybrid compounds, which were pharmacologically characterized at hH1R and hH4R. The new compounds revealed (high) affinity to hH1R, but showed only low affinity to hH4R. Additionally, we performed molecular dynamic studies for some selected compounds at hH1R, in order to obtain information about the binding mode of these compounds on molecular level.

CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS

A compound of the formula: wherein R 1 and R 2 each represents hydrogen, lower alkyl which may be substituted or acyl; R 3, R 4 and R 5 each represents lower alkyl which may be substituted or lower alkoxy which may be substituted or R 4 and R 5 taken together represent a 5-or 6-membered carbocyclic group; R 6 represents lower alkyl; Ar represents an aromatic group which may be substituted; ring A represents a 5-to 8-membered nitrogen-containing heterocyclic ring which may be substituted; X represents lower alkylene which may be substituted; Y represents carbon or nitrogen; Za represents CH 2, COCH 2, OCH 2, SCH 2, NHCH 2, etc.; Zb represents a bond or a divalent aliphatic hydrocarbon group which may be substituted and may contain O, N or S; and m represents an integer of 1 to 3, or a salt thereof is useful for a pharmaceutical composition for modulating sodium channel.

Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909)

The design, synthesis, and biological evaluation of compounds related to the dopamine (DA) uptake inhibitors: 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (1) and 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (2) (GBR